Are you Dr. Lenzi?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 44 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Renato Lenzi, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Alabama, and Arizona. He is affiliated with University of Texas M.D. Anderson Cancer Center and is an Associate Professor of Medicine at University Tex Houston.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1989 - 1990
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1983 - 1986
One Brooklyn Health System/Interfaith Medical CenterResidency, Internal Medicine, 1980 - 1983
University of Cattolica del Sacro CuoreClass of 1977
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 1986 - Present
AZ State Medical License 2023 - 2026
TX State Medical License 1990 - 2026
WA State Medical License 2023 - 2026
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- Join now to see all
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Fellow (FACP) American College of Physicians, 1999
Clinical Trials
- Interleukin-12 in Treating Patients With Cancer in the Abdomen Start of enrollment: 1997 Aug 01
- Interleukin-12 in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer Start of enrollment: 2001 Jul 01
- Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors Start of enrollment: 2005 Nov 01
Publications & Presentations
PubMed
- 70 citationsEstrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular CarcinomaManal Hassan, Gehan Botrus, Reham Abdel-Wahab, Robert A. Wolff, Donghui Li
Clinical Gastroenterology and Hepatology. 2017-11-01 - 18 citationsOccult primary, version 3.2014; Featured updates to the NCCN guidelinesDavid S. Ettinger, Charles R. Handorf, Mark Agulnik, Daniel W. Bowles, Justin M M Cates
Journal of the National Comprehensive Cancer Network. 2014-07-01 - 6 citationsA phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine in carcinoma of unknown primary.Heather R. Carlson, Renato Lenzi, Martin N. Raber, Gauri R. Varadhachary
International Journal of Clinical Oncology. 2013-04-01
Grant Support
- IP Recombinant IL-12 In Patients With Ovarian Cancer: Phase IINational Center For Research Resources2005
- IP Recombinant IL-12 In Patients With Ovarian CancerNational Center For Research Resources2004
- IP Recombinant Human IL-12 In Patients With Peritoneal CarcinomatosisNational Center For Research Resources1998–2002
- Laboratory Studies With Intraperitoneal Rhil-12 TherapyNational Cancer Institute1998
Professional Memberships
- Fellow
